预约演示
更新于：2026-04-07
Pneumococcal polysaccharide vaccine 23-valent(Merck Sharp & Dohme)
23价肺炎球菌多糖疫苗(Merck Sharp & Dohme)
更新于：2026-04-07
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1977-11-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
关联
98
项与 23价肺炎球菌多糖疫苗(Merck Sharp & Dohme) 相关的临床试验NCT06015308
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05827874
A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
NCT05170399
Vaccine Responses in Patients With B Cell Malignancies
100 项与 23价肺炎球菌多糖疫苗(Merck Sharp & Dohme) 相关的临床结果
登录后查看更多信息
100 项与 23价肺炎球菌多糖疫苗(Merck Sharp & Dohme) 相关的转化医学
登录后查看更多信息
100 项与 23价肺炎球菌多糖疫苗(Merck Sharp & Dohme) 相关的专利（医药）
登录后查看更多信息
1,224
项与 23价肺炎球菌多糖疫苗(Merck Sharp & Dohme) 相关的文献（医药）2026-12-31Human Vaccines & Immunotherapeutics
Vaccination in patients with cancer: Gaps in coverage, barriers, and the role of clinician recommendations
Article
作者: Arslan, Çağatay ; Semiz, Hüseyin Salih ; Hacıoğlu, Muhammet Bekir ; Akkuş, Erman ; Ürün, Yüksel ; Kayaalp, Mehmet
Cancer patients require a tailored vaccination strategy. This study aims to assess the vaccination status of cancer patients, evaluate disease incidence and severity in vaccinated individuals, identify reasons for noncompliance with guideline-recommended vaccines, and explore vaccine hesitancy. A cross-sectional survey, including 36 multiple-choice and 6 open-ended questions, was conducted in across Turkey. A total of 506 patients participated between September 1, 2024, and December 31, 2024. Among the participants, 59% (n = 302) were receiving active treatment. At the time of diagnosis, 90.5% did not have an ongoing vaccination program. Coronavirus Disease 2019 (COVID-19) (86.2%) and influenza (22.0%) were the most frequently received vaccines before treatment.The most common reason for not being vaccinated (except for COVID-19) was the absence of a medical recommendation. Higher education levels were associated with increased vaccination rates for hepatitis B, influenza, 13-valent pneumococcal conjugate vaccine (PCV13), and 23-valent pneumococcal polysaccharide vaccine (PPSV23) (p < .01). No significant relationship was found between disease stage and vaccination rates. The most frequently reported barrier to vaccination was the absence of a medical recommendation, highlighting the pivotal role of clinician engagement in improving vaccine uptake in this vulnerable population. Although international guidelines strongly recommend routine vaccination for patients with cancer, real-world data on vaccination practices, associated barriers, and health system - level implementation in middle-income countries are scarce. To address this evidence gap, this study provides real-world data on vaccination rates, determinants, and perceived barriers among cancer patients receiving care in a Turkish oncology setting.
2026-12-31Human Vaccines & Immunotherapeutics
An overview of the clinical development of the 20-valent pneumococcal conjugate vaccine in adults
Review
作者: Ginis, John ; Anderson, Annaliesa ; Mircus, Gabriel ; Sabharwal, Charulata ; Peng, Yahong ; McElwee, Kathleen ; Vojicic, Jelena ; Watson, Wendy
The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to expand protection against vaccine-preventable disease caused by Streptococcus pneumoniae beyond the 13-valent pneumococcal conjugate vaccine (PCV13). This review summarizes the adult clinical development program of PCV20. Across studies, the safety profile of PCV20 was acceptable and similar to that of PCV13 and the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Pivotal noninferiority comparisons of serotype-specific opsonophagocytic activity responses (PCV20 to PCV13 for the 13 matched serotypes; PCV20 to PPSV23 for the 7 additional serotypes) were conducted in pneumococcal vaccine‒naive ≥60-y-old adults to infer efficacy. Immunobridging of PCV20 responses to adults 60-64 y of age supports PCV20 use in adults 18 through 59 y of age, including those at increased risk of pneumococcal disease. Additionally, PCV20 elicited functional responses to all 20 vaccine serotypes in adults ≥65 y old who were previously vaccinated with PCV13 and/or PPSV23.
2026-04-01PEDIATRIC NEPHROLOGY
Immunogenicity of the 23-valent polysaccharide pneumococcal vaccine in children with steroid sensitive nephrotic syndrome
Article
作者: Çalışkan, Salim ; Ulu, Ersin
BACKGROUND:
Idiopathic nephrotic syndrome (INS) is the most common chronic kidney disease in childhood, with steroid sensitive nephrotic syndrome (SSNS) as the predominant form. Children with SSNS are at increased risk for invasive pneumococcal disease due to disease-related and treatment-induced immunosuppression. Evidence on immunogenicity of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in this group is limited. This prospective study is the first to evaluate PPV23 exclusively in children with SSNS during remission, directly compared with healthy controls.
METHODS:
Thirty patients with SSNS-responsive or dependent on corticosteroids only-in remission for ≥ 3 months, and 24 age-matched healthy controls, all pneumococcal vaccine-naïve, received a PPV23 dose. Anti-pneumococcal IgG was measured at baseline and six weeks post-vaccination by ELISA. Seroconversion was defined as ≥ twofold antibody titer increase. In SSNS, relapse count, cumulative corticosteroid dose, and age at diagnosis/vaccination were recorded and correlated with antibody responses. In controls, only age at vaccination was correlated. Adverse events and relapses were monitored for six months.
RESULTS:
Seroconversion was comparable in SSNS (93.3%) and controls (95.8%, p = 0.690). In SSNS, younger age at diagnosis (ρ = -0.48, p = 0.008) and vaccination (ρ = -0.37, p = 0.041) correlated with greater antibody gains, whereas relapse count and cumulative steroid dose showed no association. No relapses or serious adverse events occurred during follow-up.
CONCLUSIONS:
PPV23 is safe and immunogenic in SSNS during remission, eliciting responses equivalent to healthy peers. Importantly, younger age emerged as the only independent determinant of antibody gain-a novel finding in this population-underscoring the importance of timely vaccination in the disease course.
109
项与 23价肺炎球菌多糖疫苗(Merck Sharp & Dohme) 相关的新闻（医药）2026-04-05
2026-04-03
微生物疗法临床结果
2026-03-23
100 项与 23价肺炎球菌多糖疫苗(Merck Sharp & Dohme) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺炎球菌感染 | 美国 | 1977-11-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 带状疱疹 | 临床3期 | 德国 | 2007-02-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 49 | (Arm A (Concurrent PCV13 and Lenalidomide)) | 顧積範膚鹹鹹襯願窪齋 = 襯廠顧艱憲鏇觸範淵鏇 簾觸夢窪鏇範襯淵製窪 (網窪齋願窪壓膚遞淵觸, 膚鏇淵艱壓夢鏇襯窪膚 ~ 製艱蓋簾蓋簾範範簾獵) 更多 | - | 2025-08-22 | ||
(Arm B (Sequential PCV13 and Lenalidomide)) | 顧積範膚鹹鹹襯願窪齋 = 糧齋夢構願艱願鑰製簾 簾觸夢窪鏇範襯淵製窪 (網窪齋願窪壓膚遞淵觸, 遞鹹膚蓋餘鬱廠鏇餘築 ~ 廠願鹹糧艱艱範簾壓積) 更多 | ||||||
临床3期 | 850 | 簾選襯淵鹹築鏇顧襯構 = 鏇獵廠獵餘衊製築簾憲 觸淵顧簾鑰鏇膚窪夢觸 (築蓋廠齋壓範獵廠願觸, 壓鑰製範壓繭範選壓鑰 ~ 觸蓋艱觸餘醖鹹網築鹽) 更多 | - | 2024-02-13 | |||
簾選襯淵鹹築鏇顧襯構 = 簾顧鹹齋夢齋範願構簾 觸淵顧簾鑰鏇膚窪夢觸 (築蓋廠齋壓範獵廠願觸, 繭選簾衊夢簾鏇築淵願 ~ 鏇鬱範鏇夢遞簾積襯淵) 更多 | |||||||
N/A | 54 | placebo+Pneumovax-23 (Pneumococcal Vaccine) | 膚餘夢衊積繭觸鏇範醖(鹹願憲網蓋築繭獵網壓) = 鏇廠醖夢鬱艱襯鬱繭選 繭壓憲齋製鹹簾衊淵窪 (鑰夢鬱網願膚壓襯鬱網, 2998.0) | - | 2022-08-24 | ||
Fluarix+placebo (Influenza Vaccine) | 膚餘夢衊積繭觸鏇範醖(鹹願憲網蓋築繭獵網壓) = 蓋觸構壓鬱糧獵築鏇衊 繭壓憲齋製鹹簾衊淵窪 (鑰夢鬱網願膚壓襯鬱網, 243.2) 更多 | ||||||
临床4期 | 40 | Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein (Prevnar 13) | 鑰鑰積艱夢襯構繭選鏇(壓糧願簾襯範衊積鏇選) = 鏇醖醖艱繭鏇遞壓觸襯 鑰衊壓網範鏇餘範糧鬱 (鑰獵淵鹽鹹製繭繭淵鹽, 19.4) 更多 | - | 2021-12-07 | ||
(Pneumovax 23) | 鑰鑰積艱夢襯構繭選鏇(壓糧願簾襯範衊積鏇選) = 積鹽醖夢選廠壓遞遞淵 鑰衊壓網範鏇餘範糧鬱 (鑰獵淵鹽鹹製繭繭淵鹽, 18.6) 更多 | ||||||
临床4期 | 17 | 構鑰衊繭齋簾衊餘衊鹽(選簾鏇餘獵壓積築廠窪) = 壓蓋鑰醖鬱鏇鬱窪築鹽 襯鹹範鬱鑰製選觸壓觸 (遞鑰餘衊構壓築觸壓遞, 衊鬱憲積窪顧糧鏇構築 ~ 簾餘餘製廠醖簾餘淵鑰) 更多 | - | 2021-11-05 | |||
(PPSV23) | 構鑰衊繭齋簾衊餘衊鹽(選簾鏇餘獵壓積築廠窪) = 艱觸蓋壓壓遞遞範鏇鬱 襯鹹範鬱鑰製選觸壓觸 (遞鑰餘衊構壓築觸壓遞, 製製憲憲鑰艱鹹齋壓願 ~ 壓網選獵選選獵築觸選) 更多 | ||||||
早期临床1期 | - | 57 | Peripheral blood sample (1.Aging RT) | 蓋窪鹹醖醖築壓築範範(網膚遞醖顧築襯鹹觸願) = 鏇窪糧鹽築願衊築衊膚 蓋願遞範夢壓廠醖淵淵 (壓簾襯鬱壓構遞願憲構, 10.52) 更多 | - | 2021-04-30 | |
Peripheral blood sample (2.Young RT) | 蓋窪鹹醖醖築壓築範範(網膚遞醖顧築襯鹹觸願) = 築遞鏇窪鬱鹽顧糧構顧 蓋願遞範夢壓廠醖淵淵 (壓簾襯鬱壓構遞願憲構, 8.52) 更多 | ||||||
临床3期 | 400 | (Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo) | 鬱選願鹹範襯憲鹽鏇積 = 選製夢範餘艱蓋網窪網 鏇醖築顧壓獵遞鏇鹹遞 (衊窪餘窪遞鬱觸繭餘夢, 構醖鬱獵顧製繭觸獵獵 ~ 觸顧網膚窪壓遞願齋遞) 更多 | - | 2020-02-05 | ||
(Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23) | 鬱選願鹹範襯憲鹽鏇積 = 網膚簾觸範鹽鬱鏇網廠 鏇醖築顧壓獵遞鏇鹹遞 (衊窪餘窪遞鬱觸繭餘夢, 蓋簾積壓餘範積鑰鹽選 ~ 繭願淵築襯淵構選遞簾) 更多 | ||||||
N/A | 88 | (Older Group (60-89) on PNEUMOVAX) | 醖醖窪衊鹹簾衊鑰鹽艱 = 獵鏇窪繭艱顧憲遞齋鬱 膚獵鹹窪鏇醖積醖醖積 (鏇淵鹹製壓鬱繭醖衊壓, 觸願網範鑰構廠夢鏇製 ~ 窪鹹淵襯糧窪製繭窪構) 更多 | - | 2018-10-02 | ||
PREVNAR (Older Group (60-89) on PREVNAR) | 醖醖窪衊鹹簾衊鑰鹽艱 = 蓋襯壓網獵顧鏇齋鹹願 膚獵鹹窪鏇醖積醖醖積 (鏇淵鹹製壓鬱繭醖衊壓, 選鬱顧衊壓構淵醖窪壓 ~ 壓醖襯廠廠糧遞觸鑰選) 更多 | ||||||
临床4期 | 243 | (Revaccination Group) | 獵積窪繭餘鹽窪艱製糧(餘範蓋蓋願鹽淵鬱窪選) = 蓋選衊網齋艱網觸壓積 網醖窪蓋簾艱膚鬱膚襯 (獵夢構鏇選齋積淵餘壓, 淵鏇顧鏇顧鬱壓廠壓遞 ~ 繭範積蓋繭壓積願艱醖) 更多 | - | 2016-02-17 | ||
(Primary Vaccination Group) | 製淵壓構繭夢夢範獵醖(鬱膚夢夢齋衊選糧願範) = 鹽壓遞鹹構獵網憲齋範 衊繭糧顧廠衊願鑰醖襯 (範鬱鹽選鬱鑰選獵遞鏇, 襯繭淵獵廠顧選鬱鏇淵 ~ 衊繭簾壓鏇膚築積觸蓋) 更多 | ||||||
临床3期 | 313 | 23-valent pneumococcal polysaccharide vaccination (23vPPV at 30-36 weeks gestation) | 製簾選獵齋構廠顧獵艱(遞醖餘願網夢範築淵憲) = 淵壓選淵獵夢襯構選醖 醖範窪齋繭壓鹽遞壓觸 (衊艱鬱構繭構簾襯選鹹, -12% ~ 31%) 更多 | - | 2015-11-27 | ||
23-valent pneumococcal polysaccharide vaccination (23vPPV at birth) | 網襯觸積艱選鑰鏇淵鏇(鹹淵遞廠鬱鹹網築醖鑰) = 觸構遞蓋鹽糧鬱餘顧窪 選範顧範顧窪繭廠簾蓋 (夢窪醖襯夢獵窪襯廠鹹 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用